This company has been marked as potentially delisted and may not be actively trading. Mirati Therapeutics (MRTX) Short Interest Ratio & Short Volume Add Compare Share Share Short Interest Stock AnalysisBuy This Stock Mirati Therapeutics Short Interest DataMirati Therapeutics (MRTX) has a short interest of 4.39 million shares. This marks a -40.68% decrease in short interest from the previous month. The short interest ratio (days to cover) is 2.0, indicating that it would take 2.0 days of the average trading volume of 2.76 million shares to cover all short positions.Current Short Interest4,390,000 sharesPrevious Short Interest7,400,000 sharesChange Vs. Previous Month-40.68%Dollar Volume Sold Short$257.91 millionShort Interest Ratio2.0 Days to CoverLast Record DateDecember 31, 2023Outstanding Shares70,150,000 sharesPercentage of Shares Shorted6.26%Today's Trading Volume0 sharesAverage Trading Volume2,758,857 sharesToday's Volume Vs. Average0% Short Selling Mirati Therapeutics? Sign up to receive the latest short interest report for Mirati Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMRTX Short Interest Over TimeMRTX Days to Cover Over TimeMRTX Percentage of Float Shorted Over Time Mirati Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/31/20234,390,000 shares $257.91 million -40.7%N/A2 $58.75 12/15/20237,400,000 shares $427.65 million +56.1%N/A3.3 $57.79 11/30/20234,740,000 shares $269.00 million -22.2%N/A2.1 $56.75 11/15/20236,090,000 shares $342.32 million +31.8%N/A2.7 $56.21 10/31/20234,620,000 shares $256.55 million -0.9%N/A2 $55.53 10/15/20234,660,000 shares $260.73 million -45.8%N/A2.1 $55.95 9/30/20238,590,000 shares $374.18 million -5.1%N/A4.4 $43.56 9/15/20239,050,000 shares $299.10 million -4.3%N/A7 $33.05 8/31/20239,460,000 shares $351.91 million -1.8%N/A8 $37.20 8/15/20239,630,000 shares $382.60 million +19.6%N/A7.7 $39.73 Get the Latest News and Ratings for MRTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/20238,050,000 shares $243.67 million -7.9%N/A6.9 $30.27 7/15/20238,740,000 shares $309.66 million +1.6%N/A8.5 $35.43 6/30/20238,600,000 shares $310.72 million +6.6%N/A8.3 $36.13 6/15/20238,070,000 shares $314.49 million +13.5%N/A7.7 $38.97 5/31/20237,110,000 shares $264.21 million +5.2%N/A6.8 $37.16 5/15/20236,760,000 shares $334.21 million -14.8%N/A6.9 $49.44 4/30/20237,930,000 shares $351.38 million -13.6%N/A7.9 $44.31 4/15/20239,180,000 shares $360.32 million -0.9%N/A8.6 $39.25 3/31/20239,260,000 shares $344.29 million +7.7%N/A8.3 $37.18 3/15/20238,600,000 shares $371.26 million -2.4%N/A6.8 $43.17 2/28/20238,810,000 shares $403.85 million -3.9%N/A5 $45.84 2/15/20239,170,000 shares $446.67 million -3.9%N/A4.9 $48.71 1/31/20239,540,000 shares $509.53 million -10.3%N/A4.9 $53.41 1/15/202310,630,000 shares $458.05 million +1.0%N/A5.7 $43.09 12/30/202210,530,000 shares $477.11 million +6.6%N/A5.9 $45.31 12/15/20229,880,000 shares $420.30 million +30.0%N/A5.9 $42.54 11/30/20227,600,000 shares $694.49 million -5.9%N/A5.8 $91.38 11/15/20228,080,000 shares $585.80 million +4.5%N/A8.4 $72.50 10/31/20227,730,000 shares $520.38 million -2.3%N/A10 $67.32 10/15/20227,910,000 shares $528.78 million +2.5%N/A9.4 $66.85 9/30/20227,720,000 shares $539.16 million -3.4%N/A8.4 $69.84 9/15/20227,990,000 shares $659.10 million +7.3%N/A8.1 $82.49 8/31/20227,450,000 shares $603.67 million -1.6%N/A6.7 $81.03 8/15/20227,570,000 shares $653.44 million +8.5%N/A4.8 $86.32 7/31/20226,980,000 shares $449.51 million -13.3%13.7%4.3 $64.40 7/15/20228,050,000 shares $483.16 million -2.2%24.0%5.2 $60.02 6/30/20228,230,000 shares $552.48 million +46.7%24.5%5.6 $67.13 6/15/20225,610,000 shares $302.66 million +19.1%16.7%4 $53.95 5/31/20224,710,000 shares $184.44 million -9.6%9.2%3.9 $39.16 5/15/20225,210,000 shares $296.14 million +24.1%10.2%7.1 $56.84 4/30/20224,200,000 shares $259.52 million +14.1%8.2%5.5 $61.79 4/15/20223,680,000 shares $301.54 million +10.8%7.2%5.2 $81.94 3/31/20223,320,000 shares $272.97 million +6.8%6.5%4.7 $82.22 3/15/20223,110,000 shares $240.47 million -7.2%6.1%4.5 $77.32 2/28/20223,350,000 shares $295.77 million +12.8%7.0%5 $88.29 2/15/20222,970,000 shares $318.95 million +2.1%6.2%4.6 $107.39 1/31/20222,910,000 shares $347.16 million +11.1%6.1%5 $119.30 1/15/20222,620,000 shares $325.69 million -4.4%5.5%4.9 $124.31 12/31/20212,740,000 shares $401.93 million -11.0%5.8%5.6 $146.69 12/15/20213,080,000 shares $434.22 million +14.1%6.5%6.1 $140.98 11/30/20212,700,000 shares $369.28 million -16.2%5.7%4.9 $136.77 11/15/20213,220,000 shares $453.34 million -16.6%6.8%5.9 $140.79 10/29/20213,860,000 shares $729.62 million -5.4%8.1%8.3 $189.02 10/15/20214,080,000 shares $727.38 million +1.5%8.6%9.3 $178.28 9/30/20214,020,000 shares $711.18 million +20.4%8.5%9.2 $176.91 9/15/20213,340,000 shares $561.39 million -7.5%7.0%6.6 $168.08 8/31/20213,610,000 shares $612.73 million -0.6%7.6%8.1 $169.73 8/13/20213,630,000 shares $508.82 million No Change7.6%8.2 $140.17 7/30/20213,630,000 shares $581.02 million +0.3%7.6%7.5 $160.06 7/15/20213,620,000 shares $574.46 million +5.2%7.4%6.2 $158.69 6/30/20213,440,000 shares $555.66 million -28.0%7.1%5.7 $161.53 6/15/20214,780,000 shares $796.35 million +4.4%9.8%9.3 $166.60 5/28/20214,580,000 shares $724.33 million +2.2%9.4%9.1 $158.15 5/14/20214,480,000 shares $693.32 million +6.7%N/A8.9 $154.76 4/30/20214,200,000 shares $690.94 million +11.7%N/A8.3 $164.51 4/15/20213,760,000 shares $607.09 million -3.3%N/A8.8 $161.46 3/31/20213,890,000 shares $645.62 million +2.9%N/A9.1 $165.97 3/15/20213,780,000 shares $718.16 million +3.3%N/A8.8 $189.99 2/26/20213,660,000 shares $715.90 million +6.4%N/A8.6 $195.60 2/12/20213,440,000 shares $726.63 million -9.7%N/A8.2 $211.23 1/29/20213,810,000 shares $776.74 million -0.8%N/A8.9 $203.87 1/15/20213,840,000 shares $820.80 million +1.1%N/A7.7 $213.75 12/31/20203,800,000 shares $833.30 million -4.5%N/A7.8 $219.29 12/15/20203,980,000 shares $934.70 million -1.7%N/A8.1 $234.85 11/30/20204,050,000 shares $941.79 million +1.3%N/A7.6 $232.54 11/15/20204,000,000 shares $916 million +7.0%N/A7.5 $229.00 10/30/20203,740,000 shares $822.69 million -13.6%N/A7.2 $219.97 MRTX Short Interest - Frequently Asked Questions What is Mirati Therapeutics' current short interest? Short interest is the volume of Mirati Therapeutics shares that have been sold short but have not yet been covered or closed out. As of December 31st, investors have sold 4,390,000 shares of MRTX short. Learn More on Mirati Therapeutics' current short interest. What is a good short interest ratio for Mirati Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MRTX shares currently have a short interest ratio of 2.0. Learn More on Mirati Therapeutics's short interest ratio. Is Mirati Therapeutics' short interest increasing or decreasing? Mirati Therapeutics saw a decline in short interest in December. As of December 31st, there was short interest totaling 4,390,000 shares, a decline of 40.7% from the previous total of 7,400,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Mirati Therapeutics' short interest compare to its competitors? Here is how the short interest of companies compare to Mirati Therapeutics: Jyong Biotech Ltd. (0.45%), Zymeworks Inc. (3.24%), Aerovate Therapeutics, Inc. (21.72%), BioAge Labs, Inc. (11.12%), Whitehawk Therapeutics, Inc. (0.99%), Spruce Biosciences, Inc. (0.22%), Actinium Pharmaceuticals, Inc. (2.81%), PyroGenesis Canada Inc. (0.17%), Synaptogenix, Inc. (17.60%), NanoViricides, Inc. (1.33%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: General Motors Company ($4.15 billion), T-Mobile US, Inc. ($3.92 billion), TC Energy Corporation ($3.66 billion), Charter Communications, Inc. ($3.35 billion), Coinbase Global, Inc. ($3.32 billion), Occidental Petroleum Corporation ($2.91 billion), Tractor Supply Company ($2.80 billion), Rivian Automotive, Inc. ($2.44 billion), Moderna, Inc. ($2.41 billion), and United Rentals, Inc. ($2.23 billion). View all of the most shorted stocks. What does it mean to sell short Mirati Therapeutics stock? Short selling MRTX is an investing strategy that aims to generate trading profit from Mirati Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Mirati Therapeutics? A short squeeze for Mirati Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of MRTX, which in turn drives the price of the stock up even further. How often is Mirati Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MRTX, twice per month. The most recent reporting period available is December, 31 2023. More Short Interest Resources from MarketBeat Related Companies Jyong Biotech Short Interest Data Zymeworks Short Interest Data Aerovate Therapeutics Short Interest Data BioAge Labs Short Interest Data Whitehawk Therapeutics Short Interest Data Spruce Biosciences Short Interest Data Actinium Pharmaceuticals Short Interest Data PyroGenesis Canada Short Interest Data Synaptogenix Short Interest Data NanoViricides Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MRTX) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirati Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirati Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
